Summary
Pfizer Inc. (PFE) filed an 8-K report on March 2, 2010, detailing a significant amendment to its corporate governance structure. The Board of Directors approved changes to Article III, Section 3, of the company's By-laws on February 25, 2010. The most impactful change separates the roles of Chief Executive Officer (CEO) and Chairman of the Board, eliminating the prior presumption that the CEO would also serve as Chairman. This move is designed to enhance corporate governance by providing greater independence and potentially clearer oversight of management by the board.
Key Highlights
- 1Pfizer's Board of Directors approved an amendment to its By-laws on February 25, 2010.
- 2The amendment impacts Article III, Section 3, of the company's By-laws.
- 3The change eliminates the presumption that the Chief Executive Officer (CEO) must also hold the position of Chairman of the Board.
- 4This amendment aims to decouple the CEO and Chairman roles, fostering greater board independence.
- 5The By-laws were also clarified regarding the Chairman's responsibilities during Board of Directors' meetings.
- 6This governance change is effective immediately upon the Board's approval.
- 7The amended By-laws are incorporated by reference from Pfizer's 2009 10-K filing.